ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 105 filers reported holding ALBIREO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $8,375 | -99.9% | 387,567 | -24.2% | 0.01% | -16.7% |
Q3 2022 | $9,902,000 | +1435.2% | 511,477 | +1476.0% | 0.01% | – |
Q2 2022 | $645,000 | -64.5% | 32,454 | -46.7% | 0.00% | -100.0% |
Q1 2022 | $1,815,000 | -64.3% | 60,854 | -72.1% | 0.00% | -66.7% |
Q4 2021 | $5,077,000 | -36.9% | 217,999 | -15.5% | 0.00% | -40.0% |
Q3 2021 | $8,047,000 | -1.2% | 257,917 | +11.4% | 0.01% | 0.0% |
Q2 2021 | $8,146,000 | +7.2% | 231,554 | +7.4% | 0.01% | 0.0% |
Q1 2021 | $7,601,000 | -20.1% | 215,622 | -14.9% | 0.01% | -28.6% |
Q4 2020 | $9,508,000 | +4.3% | 253,469 | -7.2% | 0.01% | -36.4% |
Q3 2020 | $9,119,000 | +318.9% | 273,266 | +313.8% | 0.01% | +266.7% |
Q3 2018 | $2,177,000 | -41.1% | 66,035 | -36.5% | 0.00% | -40.0% |
Q2 2018 | $3,693,000 | -27.1% | 104,016 | -33.2% | 0.01% | -28.6% |
Q1 2018 | $5,068,000 | +324.8% | 155,611 | +234.0% | 0.01% | +250.0% |
Q4 2017 | $1,193,000 | +102.2% | 46,594 | +65.4% | 0.00% | +100.0% |
Q3 2017 | $590,000 | -4.5% | 28,169 | -6.1% | 0.00% | 0.0% |
Q2 2017 | $618,000 | – | 29,983 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |